Does Medicare Cover Zepbound (Tirzepatide)?

Budget Seniors,
💊❓
Medically & Policy Verified

The short answer depends on why you are taking it. Medicare covers Zepbound for one condition but not another — and a new pricing agreement changes what you will pay. Here is everything explained plainly.

© BudgetSeniors.com — Medicare Drug Coverage Education
❌
For Weight Loss
NOT Covered by Medicare
Federal law prohibits Medicare Part D from covering medications prescribed solely for weight loss or obesity management.
✅
For Sleep Apnea (OSA)
MAY Be Covered by Medicare
FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. Some Part D plans cover it for this use.
💡 10 Key Facts Before You Call Your Doctor or Plan

Zepbound (tirzepatide) is one of the most effective weight-loss medications ever studied — clinical trials showed participants losing 15 to 21 percent of their body weight in 72 weeks. But Medicare's coverage rules for this drug are complicated, and getting them wrong can mean paying $1,000 per month out of pocket when you might qualify for as little as $50. Here is exactly what every Medicare beneficiary needs to know.

  • 1 Medicare is legally prohibited from covering Zepbound for weight loss. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes medications used solely for weight loss from Part D coverage. This is not a plan decision — it is federal law. CMS proposed overturning this for 2026, but the proposal was rejected in April 2025. A new legislative pathway is now expected via the BALANCE Model in 2027.
  • 2 Medicare CAN cover Zepbound if you have obstructive sleep apnea. The FDA approved Zepbound on December 20, 2024, as the first-ever prescription medication for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Because this is a separate FDA-approved indication unrelated to weight loss, Medicare Part D plans are permitted to cover it for this use.
  • 3 Coverage for OSA is not automatic — your specific plan must list it on its formulary. Not all Part D or Medicare Advantage plans have added Zepbound for OSA yet. Some plans require prior authorization with documentation of a formal sleep study. You must check your individual plan's drug list (formulary) before assuming you are covered.
  • 4 Eli Lilly and the U.S. government struck a deal capping your copay at $50 per month. Starting as early as April 2026, Medicare beneficiaries who receive Zepbound through the government's new pricing agreement will pay no more than $50 per month. Without this agreement, the list price is $1,086 per month. This deal applies to eligible Medicare and Medicaid recipients.
  • 5 Broader Medicare coverage for weight loss is coming in 2027, not yet. The CMS BALANCE Model is a voluntary demonstration program. Medicaid pilot coverage begins May 2026. Medicare beneficiaries may access GLP-1 medications including Zepbound through a bridge demonstration starting July 2026 at the $50 copay. Full Medicare Part D expansion through the BALANCE program is expected January 2027 — but participation by plans and manufacturers is voluntary.
  • 6 Medicare's 2026 out-of-pocket drug cap is $2,100. If your plan covers Zepbound for OSA and you pay a percentage-based coinsurance before reaching the cap, your maximum yearly exposure for all covered drugs combined is $2,100 under Medicare Part D. After that, your plan covers 100% of covered drug costs for the rest of the year.
  • 7 Zepbound and Mounjaro contain the same active ingredient but are different drugs under Medicare. Both contain tirzepatide. Mounjaro is FDA-approved for Type 2 diabetes and is covered by most Part D plans for that use. Zepbound is approved for weight loss and sleep apnea. Medicare will not cover Zepbound for diabetes — only Mounjaro carries that indication. And Medicare will not cover Mounjaro for weight loss, even though the drug is identical.
  • 8 Manufacturer savings cards are NOT available to Medicare beneficiaries. The Zepbound Savings Card from Eli Lilly can lower costs to $25 per month for commercially insured patients — but Medicare, Medicaid, VA, TRICARE, and other government-program patients are explicitly excluded from this offer by law. Do not expect the savings card to help if you are on Medicare.
  • 9 Cash-pay alternatives exist and are more affordable than the list price. Through LillyDirect — Eli Lilly's direct-to-patient platform — self-pay patients can purchase Zepbound single-dose vials starting at $299 per month (2.5 mg starting dose) to $449 per month (higher maintenance doses). This requires a valid prescription and does not use insurance. It is one of the few options available for Medicare beneficiaries who do not yet qualify for covered use.
  • 10 Obesity counseling under Medicare Part B is free and available to you right now. While Medicare will not pay for Zepbound for weight loss, it does cover Intensive Behavioral Therapy for Obesity (IBT) under Part B at no cost to you, if you have a BMI of 30 or higher and your primary care provider offers it. You can receive up to 22 sessions per year at $0 copay at participating offices — a meaningful benefit that most Medicare beneficiaries never use.
💰 List Price (No Insurance)
$1,086/mo
Eli Lilly official list price for the single-dose injector pen. Retail pharmacy prices may be slightly higher.
🏛️ Medicare Copay (Agreement)
$50/mo
Lilly-U.S. government agreement cap for eligible Medicare beneficiaries. Projected to begin as early as April 2026.
🛒 LillyDirect Self-Pay
$299–$449/mo
Direct-to-patient vials without insurance. Available to Medicare patients as a cash-pay alternative through a valid Rx.

Sources: FDA.gov Dec 20, 2024 (OSA approval announcement); CMS.gov Final Rule 90 Fed. Reg. 15792 Apr 15, 2025 (rejection of weight-loss coverage expansion for 2026); Eli Lilly press release Nov 6, 2025 (Lilly-U.S. govt $50/mo cap); CNBC Jan 8, 2025 (CMS confirms Part D can cover Zepbound for OSA); GBCHealth.org Jan 2026 (BALANCE Model timeline: Medicaid May 2026, Medicare bridge July 2026, full Part D Jan 2027); SSA / Medicare.gov (Part D 2026 $2,100 OOP cap); Eli Lilly pricinginfo.lilly.com ($1,086 list price; savings card exclusion for Medicare); LillyDirect ($299–$449 self-pay vials); CMS.gov (Part B IBT obesity counseling benefit)

🛏️ How to Get Medicare to Cover Zepbound for Sleep Apnea
✅ The OSA Pathway: What CMS Confirmed

On January 8, 2025, CMS confirmed to CNBC that Medicare Part D plans may now cover Zepbound when prescribed specifically for moderate-to-severe obstructive sleep apnea in adults with obesity. This is because the FDA's December 2024 approval gave Zepbound a second, non-weight-loss indication — and federal law only prohibits covering drugs prescribed solely for weight loss. The OSA indication creates a legal pathway. Your doctor must prescribe it for sleep apnea, not for weight management, to trigger potential coverage.

To access Zepbound through Medicare for sleep apnea, you generally need to meet all of the following criteria and follow this process:

  1. 1 Get formally diagnosed with moderate-to-severe obstructive sleep apnea. This requires a sleep study (polysomnography or home sleep apnea test) that shows an Apnea-Hypopnea Index (AHI) of 15 or more events per hour. A clinical diagnosis alone is not sufficient — documented test results are required for prior authorization.
  2. 2 Confirm your BMI is 27 or higher. The FDA's OSA approval applies to adults with obesity (BMI ≥30) or adults with overweight (BMI ≥27) who have a weight-related comorbid condition. Your current BMI must be documented in your medical record.
  3. 3 Check whether your specific plan's formulary includes Zepbound for OSA. Log into your Medicare plan's member portal, or call the Member Services number on your card. Ask specifically: “Is tirzepatide (brand name Zepbound) listed on your formulary for ICD-10 code G47.33 (obstructive sleep apnea)?” Plans are not required to add it — coverage varies.
  4. 4 Have your prescribing doctor submit a prior authorization request. Most plans that cover Zepbound for OSA require prior authorization. Your doctor must submit the request using ICD-10 diagnosis code G47.33 (Obstructive Sleep Apnea) as the primary diagnosis. BMI codes (Z68.3x–Z68.4x) can be listed as secondary. The request must include your sleep study results, BMI documentation, and in some plans, evidence that CPAP therapy was tried and failed or is not tolerated.
  5. 5 If denied, file a formal appeal within the deadline. Research shows that more than 65% of properly documented insurance appeals for Zepbound succeed. Your denial letter will include appeal instructions and a deadline (typically 60 days). Your doctor's office can assist with this process. You also have the right to request an expedited appeal if your health situation is urgent.
⚠️ Critical Prescription Detail Doctors Sometimes Miss

When your doctor sends the prescription to the pharmacy, the primary diagnosis code on the prescription must be G47.33 (Obstructive Sleep Apnea) — not an obesity code (E66.x) or a weight management code (Z71.3). If the primary diagnosis reflects weight loss or obesity management, Medicare will reject the claim regardless of your sleep apnea diagnosis. This is a common reason claims are incorrectly denied. Ask your doctor specifically to confirm the primary ICD-10 code before the prescription is submitted.

Sources: CMS.gov (confirmed OSA coverage pathway via CNBC Jan 8, 2025); FDA.gov Dec 20, 2024 (OSA approval; AHI ≥15 criteria; obesity/overweight eligibility); FindHonestCare.com Jan 2026 (ICD-10 G47.33 as primary code; BMI secondary codes; prior auth documentation requirements); GBCHealth.org Jan 2026 (65%+ appeal success rate with proper documentation; prior auth 88% of covered patients); SleepApnea.org Dec 2025 (BMI ≥27 requirement; sleep study confirmation; CPAP failure documentation)

❌ What Medicare Will Not Pay For (And Why)
📜 The Law Behind the Coverage Gap

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) includes an explicit statutory exclusion: Medicare Part D plans may not cover drugs used for “weight loss, weight gain, or anorexia.” This was written before modern GLP-1 medications existed, when Congress viewed weight-loss drugs as lifestyle products rather than medical treatments. Despite overwhelming clinical evidence that obesity is a chronic disease with serious health consequences — and that treating it reduces heart disease, diabetes, and other expensive conditions — Congress has not yet updated the law. CMS tried to reinterpret the exclusion administratively for 2026, but the proposal was withdrawn under the new administration in April 2025.

🚫 Specifically, Medicare Will NOT Cover Zepbound For:
  • Weight loss or obesity management — even though Zepbound is FDA-approved for this. The statutory exclusion applies regardless of FDA approval.
  • Type 2 diabetes — Zepbound does not carry an FDA diabetes indication. Mounjaro (same active ingredient) is the approved diabetes drug; Zepbound is not interchangeable under Part D formularies.
  • Cardiovascular disease prevention — Wegovy (semaglutide) carries a cardiovascular risk-reduction indication and may be covered by some plans for this use; Zepbound does not currently have this indication.
  • Central sleep apnea (CSA) — The FDA approval is specifically for obstructive sleep apnea, which is caused by a physical airway blockage related to weight. Central sleep apnea, which is neurological in origin, is not included.
  • Off-label or preventive use — Even if your doctor prescribes Zepbound for prediabetes, insulin resistance, or general cardiovascular prevention, Medicare Part D will not cover it for those unapproved uses.

Sources: MMA 2003 §1860D-2(e)(2)(A) (statutory weight-loss drug exclusion); CMS Final Rule 90 Fed. Reg. 15792 Apr 2025 (withdrawal of weight-loss coverage expansion proposal); FDA.gov (Zepbound approved indications: weight loss + OSA only; no diabetes or cardiovascular indication); MedicalNewsToday (Oct 2025; diabetes/Mounjaro distinction); SleepFoundation.org Dec 2025 (OSA vs CSA distinction); ASPE/HHS analysis (off-label coverage prohibited)

💵 What You Will Actually Pay: A Full Cost Breakdown
📊 Understanding the $50 Per Month Government Agreement

In November 2025, Eli Lilly announced an agreement with the U.S. government to provide Zepbound to Medicare and Medicaid beneficiaries at a dramatically reduced cost. Eligible Medicare beneficiaries will pay no more than $50 per month for Zepbound through a multi-dose KwikPen, with the program expected to begin as early as April 2026. This is a voluntary pricing arrangement, not a Part D formulary change — it works through a separate direct-to-patient channel. The $50 cap applies after your deductible is met and is separate from the standard Part D formulary pathway.

Scenario Who It Applies To Monthly Cost Notes
Lilly-Govt Agreement Eligible Medicare beneficiaries (BMI ≥27, obesity/overweight) ~$50/mo Multi-dose KwikPen. Projected start April 2026. After deductible.
Medicare Part D (OSA, covered plan) Part D enrollees with an OSA diagnosis whose plan lists Zepbound Varies by plan Subject to Part D deductible ($590), tier coinsurance, and $2,100 annual OOP cap.
LillyDirect Self-Pay Vials Anyone with a valid Rx — no insurance required $299–$449/mo Single-dose vials by dose strength. Starting dose 2.5 mg = $299. Maintenance doses (7.5–15 mg) = $449.
Retail Pharmacy (No Insurance) Cash-pay patients at standard pharmacy ~$1,086/mo Eli Lilly official list price. Retail prices slightly higher. GoodRx brings to ~$499–$995 at some pharmacies.
Commercial Insurance + Savings Card Privately insured patients (NOT Medicare/Medicaid) $25/mo Requires commercial insurance coverage. Medicare beneficiaries are explicitly excluded from this program.
❓ What Is the Part D Deductible for Zepbound?

In 2026, Medicare Part D plans may charge a deductible up to $590 per year. Until you meet this deductible, you pay 100% of the cost of covered drugs — including Zepbound if it is on your plan's formulary. After the deductible, your cost depends on the tier Zepbound is placed on (specialty tier drugs typically carry 25% to 33% coinsurance). Your total annual out-of-pocket cost for all covered drugs is capped at $2,100 in 2026. After that cap is reached, Medicare pays 100% for the rest of the year. For a high-cost specialty drug like Zepbound, many patients reach the $2,100 cap earlier in the year than they expect.

Sources: Eli Lilly press release Nov 6, 2025 (govt agreement; $50/mo; April 2026 start; multi-dose KwikPen); LillyDirect (self-pay vial pricing $299–$449; Dec 2025 price reduction); Wellcare 2026 Medicare guide (Part D deductible up to $590; 25% coinsurance; $2,100 OOP cap); GoodRx Jan 2026 ($1,086 list price; $499 GoodRx coupon low-end; savings card Medicare exclusion per Lilly terms); SleepApnea.org Dec 2025 (Part D $2,100 cap; $160–$190 average monthly under cap)

❓ Frequently Asked Questions

Not under current law. If the prescription is written specifically for weight loss or obesity management, Medicare Part D is legally prohibited from covering it, regardless of your medical need or the clinical evidence supporting treatment. This has been federal law since 2003 and CMS's attempt to change it administratively was rejected in April 2025.

The most realistic path to Medicare coverage for weight loss is the BALANCE Model — a voluntary CMS demonstration program that could bring full Medicare Part D coverage for GLP-1 obesity drugs beginning January 2027. However, participation by drug manufacturers and Part D plans is voluntary, so not all plans will offer it immediately. Additionally, the Lilly-government pricing agreement (projected April 2026) may provide a $50/month pathway for eligible Medicare beneficiaries with obesity or overweight through a direct channel separate from standard Part D formularies.

No — even though both drugs contain identical active ingredients at identical doses. Mounjaro (tirzepatide) is FDA-approved for Type 2 diabetes and is covered by most Medicare Part D plans for that indication. Zepbound (tirzepatide) is FDA-approved only for weight loss and sleep apnea — it does not have a diabetes approval. Medicare coverage is indication-specific and tied to the branded drug name on the prescription, not just the active ingredient.

If your doctor writes “Zepbound” on the prescription for diabetes management, Medicare will deny it because Zepbound is not approved for diabetes. Your doctor must prescribe Mounjaro by name for diabetes coverage under Part D. Conversely, if your plan covers Zepbound for sleep apnea, they must write “Zepbound” with the OSA diagnosis code, not Mounjaro. The two drugs cannot be substituted in either direction on Medicare formularies.

Obstructive sleep apnea (OSA) is a condition where the muscles in your throat relax during sleep, causing the upper airway to narrow or close repeatedly throughout the night. Each time this happens, your brain briefly wakes you up to reopen the airway — often without your awareness. The result is fragmented sleep, low overnight oxygen levels, and serious health consequences including high blood pressure, heart disease, stroke, and daytime fatigue. Obesity is a major risk factor because excess weight around the neck and throat narrows the airway.

The formal diagnostic criterion is the Apnea-Hypopnea Index (AHI) — the number of breathing disruptions per hour of sleep. Moderate sleep apnea is 15 to 29 events per hour; severe is 30 or more. Common symptoms include loud snoring, waking with a gasping or choking sensation, morning headaches, excessive daytime sleepiness, and a partner reporting observed breathing pauses during sleep. Diagnosis requires an overnight sleep study (polysomnography at a sleep center or a home sleep apnea test ordered by your doctor). Medicare Part B covers diagnostic sleep studies when ordered by a physician.

Zepbound is a prescription medication that has been through extensive clinical trials. The most common side effects are gastrointestinal and typically occur early in treatment as the body adjusts to the medication: nausea, diarrhea, vomiting, constipation, abdominal discomfort, and burping. These effects tend to be most pronounced when the dose is first started or increased and usually improve over several weeks. Most people can manage them without stopping treatment.

More serious risks that the FDA requires to be disclosed:

  • Thyroid tumors: Zepbound caused thyroid C-cell tumors in animal studies. It is unknown whether this applies to humans. Do not use Zepbound if you or a family member has had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Pancreatitis: Inflammation of the pancreas has been reported. Stop Zepbound and call your doctor immediately if you have severe, persistent abdominal pain that radiates to your back.
  • Low blood sugar (hypoglycemia): Risk is increased when Zepbound is taken alongside sulfonylurea drugs or insulin.
  • Serious allergic reactions: Seek emergency care for swelling of the face, lips, tongue, or throat; difficulty breathing; severe rash; or rapid heartbeat.
  • Kidney injury and gallbladder disease have also been reported.

Zepbound is injected once weekly under the skin (subcutaneous injection) at the thigh, abdomen, or upper arm. It is not approved for use in children and is not for use in people with Type 1 diabetes.

Zepbound's clinical results are among the strongest ever recorded for any prescription weight-loss medication:

  • Weight loss: In the SURMOUNT-1 clinical trial supported by Eli Lilly, participants taking the highest doses (10 mg and 15 mg) lost an average of 21% of their starting body weight — roughly 48 pounds on average — over 72 weeks. About one-third of participants at the highest dose lost 25% or more of their body weight.
  • Sleep apnea (OSA): In the SURMOUNT-OSA trials, Zepbound reduced breathing disruptions during sleep by more than 50%. After one year, 42% to 50% of participants (depending on whether they also used PAP therapy) experienced either remission or mild, non-symptomatic OSA — compared to 14–16% on placebo. Participants lost an average of 18–20% of their body weight in these trials as well.
  • Long-term use: Zepbound is intended for long-term use. Stopping the medication typically leads to weight regain. Clinical studies show that continuing treatment maintains the weight loss achieved during the initial 72-week period.

People begin seeing weight loss as early as 4 weeks after starting Zepbound. The rate and amount of weight loss depend on the dose, individual metabolism, diet, and physical activity.

Yes — and this is one of the most underused benefits in all of Medicare. Medicare Part B covers Intensive Behavioral Therapy for Obesity (IBT) at $0 cost to you (no deductible, no copay) if you meet these criteria:

  • You have a BMI of 30 or higher
  • Your primary care doctor, nurse practitioner, or physician assistant provides the counseling (it must be in a primary care setting, not a specialist office)

The benefit allows up to 22 face-to-face counseling sessions per year: one initial session of at least 30 minutes, then up to 11 monthly follow-up sessions of at least 15 minutes each, and then (if you achieve 3 kg of weight loss) up to 10 additional bi-monthly sessions. The sessions focus on setting weight-loss goals, improving diet, increasing physical activity, and behavioral change strategies. This benefit does not include prescription medications — but it is a free resource worth using while you navigate medication access or prior authorization.

Zepbound is available in two formats:

  • Single-dose injector pens (prefilled): These are the standard version dispensed at retail pharmacies. Each pen contains one dose of medication. You receive four pens per month (one per week). List price: $1,086/month at all dose strengths. Through GoodRx coupons at retail pharmacies, the price can drop to $499–$995 depending on location and pharmacy.
  • Single-dose vials (LillyDirect): Ordered directly from Eli Lilly and shipped to your home. You draw the medication from the vial using a syringe — the same technique as insulin self-injection. These are available at significantly lower prices: $299/month (2.5 mg starter), $399 (5 mg), $449 (7.5–15 mg). A valid prescription from a licensed provider is required.
  • KwikPen (multi-dose): A newer monthly multi-dose pen that contains all four weekly doses in one device. This is the format covered under the Lilly-government agreement at the $50/month cap for eligible Medicare and Medicaid beneficiaries.

For Medicare patients who do not yet qualify for covered use, the LillyDirect vials are generally the most affordable self-pay option. The vials are not available through standard retail pharmacies — they must be ordered through the LillyDirect platform with a valid prescription.

Yes — Zepbound is a qualifying prescription medication for both HSA and FSA funds. If you have a Health Savings Account from a previous employer or spouse's employer (Medicare beneficiaries cannot contribute to an HSA but can use existing funds), you can use those tax-advantaged dollars to pay for Zepbound at any price point — including the retail list price, LillyDirect vials, or any co-insurance on a covered plan. FSA funds work the same way for qualifying medical expenses including prescription drugs.

Note that most Medicare beneficiaries cannot contribute new money to an HSA once they are enrolled in Medicare Part A or Part B. But existing HSA balances accumulated from prior years carry over indefinitely and can be used for qualified medical expenses including prescription drugs at any age. This is an underused resource for Medicare patients who have prior-year HSA savings.

Sources: Drugs.com/medical-answers (Mounjaro vs Zepbound Medicare distinction; indication-specific coverage); FDA.gov (Zepbound safety information; thyroid tumor warning; pancreatitis; contraindications; SURMOUNT-OSA trial results); Eli Lilly SURMOUNT-1 trial results (15-21% weight loss; 48 lbs average; 25% loss in one-third at highest dose); Eli Lilly SURMOUNT-OSA (42-50% OSA remission; 45-50 lbs avg weight loss); CMS.gov (IBT for Obesity Part B benefit; 22 sessions; BMI ≥30; $0 copay); MedicalNewsToday; LillyDirect (vial pricing; KwikPen format); IRS Publication 502 (HSA/FSA qualifying expenses include prescription drugs)

📋 If Medicare Won't Cover Zepbound: Your Full List of Alternatives
💰 Six Ways to Access Zepbound or Similar Treatment Without Standard Medicare Coverage
  • Lilly-Government Agreement ($50/month): Starting as early as April 2026, eligible Medicare beneficiaries with obesity or overweight (BMI ≥27) may access Zepbound through a new government-negotiated pricing program at $50/month. Check lilly.com or medicare.gov for enrollment details as this program launches.
  • LillyDirect Self-Pay Vials ($299–$449/month): Order directly through LillyDirect at lilly.com with a valid prescription. No insurance needed. Starting dose (2.5 mg) is $299/month. This is currently the most accessible self-pay option for Medicare beneficiaries not yet covered for OSA.
  • GoodRx or SingleCare Coupons at Retail Pharmacies: While significantly below the $1,086 list price, coupon-based pricing for the prefilled pens still runs $499–$995 at most pharmacies — substantially more than LillyDirect vials. These are best used when the prefilled pen format is preferred over self-injection vials.
  • Lilly Cares Patient Assistance Program: Eli Lilly's charitable assistance program covers certain medications for qualifying low-income patients. Call 1-800-545-6962 or visit lillycares.com to ask whether Zepbound is included and what income thresholds apply. Availability for Zepbound is not guaranteed but may expand over time.
  • Medicare Part B Obesity Counseling (FREE): Available to any Medicare beneficiary with a BMI ≥30 at no cost through your primary care provider. Up to 22 sessions per year at $0 copay. Not a medication — but a free covered benefit that supports weight management and is often combined with other treatments.
  • Medicare-Covered Bariatric Surgery: Medicare covers certain weight-loss (bariatric) surgeries — including laparoscopic Roux-en-Y gastric bypass, laparoscopic adjustable gastric banding, and open gastric bypass — when performed at Medicare-certified facilities and when medical necessity criteria are met. Over several years, the annual cost of Zepbound at full self-pay prices can exceed the total cost of a single bariatric procedure. Ask your doctor whether you qualify.

Sources: Eli Lilly press release Nov 6, 2025 (govt agreement $50/mo; April 2026 timeline; BMI ≥27 eligibility); LillyDirect pricing page (vials $299–$449; valid Rx required); GoodRx.com Jan 2026 ($499+ GoodRx coupon at pharmacies); LillyCares.com 1-800-545-6962 (patient assistance program inquiry); CMS.gov (Part B IBT obesity counseling; 22 sessions; $0 copay; BMI ≥30); GrandHealthPartners.com Jan 2026 (bariatric surgery Medicare coverage; long-term cost comparison)

📅 What Is Expected to Change — and When
  • April 2026 (projected): Lilly-U.S. government agreement takes effect. Eligible Medicare and Medicaid beneficiaries with obesity (BMI ≥27) may access Zepbound via multi-dose KwikPen at a $50/month copay through a new government pricing channel. Details and enrollment process to be announced at medicare.gov and lilly.com.
  • May 2026: CMS BALANCE Model pilot begins for Medicaid in participating states. Select Medicaid programs begin coverage for GLP-1 obesity medications.
  • July 2026: CMS BALANCE Model bridge demonstration for Medicare begins. Some Medicare beneficiaries may access GLP-1 medications including Zepbound for weight management at the $50/month rate through participating plans and manufacturers.
  • January 2027: Full Medicare Part D expansion under BALANCE Model expected to begin. Participation by plans and drug manufacturers is voluntary — coverage will not be universal across all Medicare plans on day one. Check your plan's formulary during the 2027 Annual Enrollment Period (October–December 2026) to see if your plan is participating.
  • What will NOT change: The statutory Medicare weight-loss drug exclusion in the MMA 2003 remains in federal law unless Congress passes new legislation. The BALANCE Model is a CMS demonstration program that works around the statute — not a permanent legislative fix. Full, guaranteed Medicare coverage for all obesity medications requires an act of Congress.
❓ Five Questions to Ask Your Doctor at Your Next Appointment
  • Do I have undiagnosed obstructive sleep apnea? If you snore, wake up tired, or have been told you stop breathing during sleep, ask for a referral for a sleep study. A positive diagnosis could open the Medicare OSA coverage pathway for Zepbound.
  • If you prescribe Zepbound for OSA, will you use ICD-10 code G47.33 as the primary diagnosis? This specific code is required for Medicare Part D coverage. Confirm this detail before the prescription is submitted to the pharmacy.
  • Does my specific Medicare plan's formulary currently include Zepbound for sleep apnea? Coverage varies by plan. Your doctor or their office staff can often check this in real time during your appointment.
  • Do I qualify for Medicare Part B Intensive Behavioral Therapy for Obesity? If your BMI is 30 or higher, this benefit is available at no cost to you through your primary care provider — but you must ask for it specifically.
  • Am I a candidate for bariatric surgery under Medicare? If you have a BMI of 35 or higher with a comorbid condition (diabetes, high blood pressure, sleep apnea), you may qualify for Medicare-covered weight-loss surgery, which may be a more cost-effective long-term solution than self-paying for medications indefinitely.

Medical Disclaimer: This guide is for informational purposes only and does not constitute medical or insurance advice. Drug coverage rules, formularies, and pricing agreements change frequently. Always verify current coverage with your Medicare plan and consult your prescribing physician before starting, stopping, or changing any medication. © BudgetSeniors.com

Sources: GBCHealth.org Jan 2026 (BALANCE Model timeline: Medicaid May 2026, Medicare bridge July 2026, Part D Jan 2027; voluntary participation); Eli Lilly Nov 2025 press release (April 2026 $50/mo start); MMA 2003 §1860D-2(e)(2)(A) (statutory exclusion); CMS.gov (AEP Oct-Dec 2026 for 2027 plans); FindHonestCare.com Jan 2026 (ICD-10 G47.33 prior auth requirements); CMS.gov (IBT obesity counseling Part B); Medicare.gov (bariatric surgery coverage criteria; BMI ≥35 + comorbidity); BudgetSeniors.com editorial research March 2026

Recommended Reads

  1. 12 Best Free Checking Accounts for Seniors
  2. Aetna Senior Products: Complete Eligibility & Coverage Guide
  3. Does Spectrum Have a Senior Discount?
  4. How Much Is a Costco Membership?
  5. How Much Does Starlink Equipment Cost?
  6. 20 Balance Transfer Credit Cards: No or Low Fee Options
⚕️ Health & Insurance

Leave a Reply

Your email address will not be published. Required fields are marked *

Resize text